Hanlim Pharm. Co., Ltd.
Quick facts
Marketed products
- Placebo of Venitol Tab.
This is a placebo formulation with no active pharmacological mechanism. - Risedronate/Cholecalciferol combination · Bone metabolism / Osteoporosis
Risedronate inhibits bone resorption by blocking osteoclast activity, while cholecalciferol (vitamin D3) enhances calcium absorption and supports bone mineralization. - Venitol Tab. · Cardiovascular
Venitol is a venotropic agent that improves venous tone and microcirculation by enhancing vascular endothelial function.
Phase 3 pipeline
- Active comparator1 : Ezetimibe / Rosuvastatin · Cardiovascular
This combination reduces LDL cholesterol through dual inhibition of cholesterol absorption (ezetimibe) and hepatic cholesterol synthesis (rosuvastatin). - Active comparator2 : Telmisartan · Cardiovascular
Telmisartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. - Charcotrace Inj. · Neurology / Diagnostic Imaging
Charcotrace is a diagnostic imaging agent used to visualize and trace neural pathways and lesions in the central and peripheral nervous system. - Experimental : Ezetimibe / Rosuvastatin + Telmisartan · Cardiovascular
This combination reduces cholesterol and blood pressure by inhibiting intestinal cholesterol absorption and HMG-CoA reductase while blocking angiotensin II receptors. - HL140 10/10
HL140 10/10 is an investigational drug with an undisclosed mechanism of action. - HL140 20/10
HL140 20/10 is a fixed-dose combination product from Hanlim Pharm that combines two active pharmaceutical ingredients in a 20/10 mg ratio. - HL140 5/10 · Oncology
HL140 5/10 is a small molecule that targets the PD-1/PD-L1 pathway. - HL151
HL151 is an investigational therapeutic agent in phase 3 development by Hanlim Pharm, with mechanism details not publicly disclosed. - HL301(Experimental) · Oncology
HL301 is an experimental drug that targets the PD-1/PD-L1 pathway to enhance anti-tumor immune response. - mometasone furoate plus azelastine HCl · Ophthalmology
Mometasone furoate is a corticosteroid that reduces inflammation, while azelastine HCl is an antihistamine that blocks histamine receptors. - Placebo(for Risedronate)
Placebo does not have a known mechanism of action as it is an inactive substance. - risedronate combine · Osteoporosis
Risedronate combines with other medications to inhibit bone resorption by acting on osteoclasts. - Talion Tab · Diabetes
Talion Tab is a small molecule that inhibits the activity of a specific enzyme. - Umkamin(Active Comparator) · Diabetes
Umkamin is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Phase 2 pipeline
Phase 1 pipeline
- Celecoxib plus Rebamipide
- Cohort 1: HL217 Ophathalmic Solution QD
- Cohort 2: HL217 Ophathalmic Solution BID
- Cohort 2: HL217 Ophathalmic Solution QID
- Cohort 3: HL217 Ophthalmic Solution QID
- LodineT
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: